Albany Molecular Research (AMRI) has slipped again in the fourth
quarter of 2006 recording an operating loss of $2.5m (€1.9m) - six
per cent worse than the same quarter the previous year - despite
encouraging revenue growth in its...
A new start up company in the UK has been formed with ambitions to
shape itself into a global early-phase drug development services
group through an acquisition-based strategy.
Contract manufacturer Lonza has completed its acquisition of two
Cambrex subsidiaries, research bioproducts and microbial
biopharmaceutical, in a move that is fuelled by its strategic move
into biopharmaceuticals.
Pfizer's latest cutbacks will provide a new outsourcing opportunity
for contract manufacturing organisations (CMOs) in low-cost
destinations as the drug giant announces plans to double its amount
of drug production outsourcing.
Johnson Matthey has announced a reassuring business update ahead of
its 31 March year-end, suggesting that Adderall is the driving
force behind a recovery in its pharmaceutical materials business.
UK biotech company Verona Pharma has contracted fellow UK firm Onyx
to manufacture supplies of its new hay fever drug candidate for
forthcoming preclinical and clinical studies.
Swiss chemicals firm and contract manufacturer Lonza has announced
18 per cent rise in net profit in 2006 rising to CHF 222m (€137.4),
fuelled by its strategic move into biopharmaceuticals.
Canadian contract manufacturer QSV Biologics has signed two
manufacturing deals in as many weeks, strengthening its position in
the Phase II and III clinical supplies arena.
German fine chemicals company Saltigo is benefiting from a cash
injection from its parent company, Lanxess. The German firm is
earmarking €30m for plant modernisation at its subsidiary, and a
€10m brand new multi-purpose facility...
Tocris, a leading supplier of chemicals, peptides and antibodies to
the major pharmaceutical companies, universities and research
institutes has completed a $40m (€30.8m) management buy out (MBO)
from its founders.
The booming pharmaceutical contract research market sees a new
player enter the arena as analytical lab Eno River Labs separates
into two independent divisions to create a new business that will
provide analytical and formulation...
Helix BioPharma and BioVectra have signed a deal for the
manufacture of Helix's new lung cancer drug for clinical trials - a
move that strengthens the already existing relationship between the
two Canadian firms.
Pfizer has entered a capacity expansion phase, to meet requirements
of global manufacturing of Genotropin (somatropin), a top-selling
human growth hormone.
Solvay has contracted Novasep to provide synthesis of two active
pharmaceutical ingredients, following Novasep's decision to combine
synthesis and processing expertise.
Schwarz Pharma has awarded an engineering and procurement contract
to a Jacobs Engineering Group subsidiary for the development of a
new active pharmaceutical ingredient (API) manufacturing facility
in Ireland.
Galapagos is to spend up to €19.1m to acquire Inpharmatica in order
to accelerate their drug discovery capabilities, especially in the
early stages of development.
Swiss custom manufacturer Lonza and Singapore's BioOne Capital have
announced a new joint venture to build a $350m (€263m) large-scale
manufacturing facility in Singapore.
AAIPharma has announced it has signed a contract manufacturing
agreement with Mallinckrodt Pharmaceuticals Outsourcing which aims
to provide a "one-stop drug development solution" for drug makers.
Cardinal Health, the leading contract manufacturer for the
pharmaceutical industry, has announced its plans to sell its drug
manufacturing and packaging unit in order to focus on its
health-care business.
Biotech company Progen has decided to manufacture its new
anti-cancer drug in-house rather than outsource it in order to save
on costs after the FDA gave the thumbs up for the manufacture of
the drug for its upcoming phase III clinical...
Actavis has announced its majority purchase of Russian
pharmaceutical manufacturer, ZiO Zdorovje, in a move set to
establish the company's presence in the growing Russian generics
market.
Dor BioPharma has announced it has made progress with the
formulation of RiVax, a new drug that could be the world's first
vaccine for the deadly ricin toxin.
Lonza has signed two separate deals with California-based Genentech
- a move that illustrates the re-emergence of a relationship
between the two firms.
A year after it published its five-year strategy: Vision 2010 -
Building on Strengths - DSM's commitment is showing no sign of
slowing as is continues to invest in the expansion of its
pharmaceutical production capabilities around...
US-based drug maker Cleveland BioLabs has teamed up with
biopharmaceutical manufacturer Synco Bio Partners to produce its
leading radioprotection molecule for clinical trials and
commercialisation
Curalogic, a Danish biotechnology company, has appointed SAFC's
Pharma business segment to provide protein isolation, extraction
and purification services as part of its product development to
treat Allergic Rhinitis.
Eli Lilly has splashed out $2.1bn (€1.7bn) to buy ICOS, who the
drug giant has been involved in a joint venture with to manufacture
and sell Cialis (tadalafil) - the number two erectile dysfunction
drug behind Viagra (sildenafil).
UK Biopharma company Evolutec has signed a deal with Wacker Biotech
to produce Evolutec's new autoimmune disease drug candidate rEV576
for clinical trials.
Two trade associations of the world's two largest pharma economies
- Europe and the US - took the unusual step of banding together at
the CPhI in Paris to condemn their regulatory authorities for poor
regulation of foreign active...
Sigma-Aldrich Group member SAFC made its presence felt at the
recent CPhI in Paris with announcements regarding its expansion
activities in transgenic manufacturing and India.
Pfizer CentreSource has decided to outsource the manufacture of some of its active pharmaceutical ingredients (API) to two Asian contract manufacturers and intends to work with the Food and Drug Administration's (FDA) during the process.
ClinTec International and Dr. Reddy's Laboratories have announced a
partnership, in which both parties are to jointly develop an
anti-cancer drug that belongs to the topoisomerase inhibitors class
of compounds.
In its ambition to become one of the top three global players in
custom manufacturing, the UK subsidiary of drug-maker Nicholas
Piramal (NPIL) has created a new "innovation unit" in Europe.
According to a new report, pharmaceutical and biotech companies
have not fully exploited the potential outsourcing represents,
having only been adopted to a limited extent to date by companies.
Contract Research Organisations (CROs) have acquired an enviable
reputation for providing a good quality service that is carried out
by experienced staff, delivering all to budget and on time. But is
outsourcing early phase clinical...
Drug developing services provider Aptuit has acquired the
pharmaceutical services division of technology firm EaglePicher,
enriching its active pharmaceutical ingredient (API) and drug
substance manufacturing offerings.
US contract pharmaceutical manufacturer Metrics has announced a
$17.5m (€13.7m) investment to double the size of its drug testing
and manufacturing plant over the next three years.
According to a senior figure in the outsourcing industry, high
content screening (HCS) is set to overtake current methods as the
preferred technique of generating hits with the greatest interest
coming from the oncology sector.
Solvents are defined as organic chemicals that are used to dissolve components. They are used during the manufacture of drug substances and can also potentially...
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...
